Brilique recommended for use by Germany’s pricing watchdog
pharmafile | December 19, 2011 | News story | Sales and Marketing | AstraZeneca, Brilique, Plavix
Germany’s new pricing committee has said that AstraZeneca’s Brilique is a cost effective treatment for patients with a certain heart condition.
The Federal Joint Committee (G-BA) has said that AZ’s oral antiplatelet treatment Brilique (ticagrelor) was cost effective for people with acute coronary syndromes.
Its assessment said it provides an additional benefit to around 80% of the acute coronary syndromes (ACS) patient population in Germany, compared with other treatments.
It also said Brilique performed better than Sanofi/BMS’s standard treatment Plavix (clopidogrel), plus aspirin, in the non ST-elevation myocardial infarction/unstable angina population.
The G-BA has determined that the drug offers an ‘important additional benefit’ in this patient population.
Under new legislation passed in the country earlier this year, all drugs without the additional benefit will priced lower than Brilique.
Brilique is the first drug to be evaluated under the new AMNOG (reorganisation of the pharmaceutical market) legislation, which was passed in Germany at the beginning of the year to help regulate the prices of newly approved drugs.
This legislation established the G-BA to work with the existing Institute for Quality and Efficiency in Healthcare (IQWiG), a pricing watchdog similar to the UK’s NICE.
Its raison d’être is to scrutinise the cost effectiveness of new drugs in an attempt to keep the country’s drug bill down.
Both now work together to assess a new drug’s cost effectiveness against a suitable comparator and if the drug fails to demonstrate this, then its manufacturer may be liable to refund the government’s Statutory Health Fund, which originally paid for the treatment.
IQWiG already gave the drug a positive opinion in October, and AstraZeneca is to begin pricing discussions in January with the Federal Association of Statutory Health Insurance Funds.
Adam Hill
Related Content
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …
AstraZeneca withdraws COVID-19 vaccine Vaxzevria
UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …
